Industry insiders expect GSK's mainland drug sales growth to slow sharply or even reverse in the third quarter, after rising 14 per cent in the second quarter. Photo: Reuters Industry insiders expect GSK's mainland drug sales growth to slow sharply or even reverse in the third quarter, after rising 14 per cent in the second quarter. Photo: Reuters
Industry insiders expect GSK's mainland drug sales growth to slow sharply or even reverse in the third quarter, after rising 14 per cent in the second quarter. Photo: Reuters

Scandal hits China drug sales

Crackdown badly affects foreign and local pharmaceutical suppliers as hospital doctors refuse to meet company reps

Industry insiders expect GSK's mainland drug sales growth to slow sharply or even reverse in the third quarter, after rising 14 per cent in the second quarter. Photo: Reuters Industry insiders expect GSK's mainland drug sales growth to slow sharply or even reverse in the third quarter, after rising 14 per cent in the second quarter. Photo: Reuters
Industry insiders expect GSK's mainland drug sales growth to slow sharply or even reverse in the third quarter, after rising 14 per cent in the second quarter. Photo: Reuters
READ FULL ARTICLE